AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29124959 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological planning prepractice
Number of subjects: 1
Study 29124959 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no prepractice)
Number of subjects: 1
Study 26879784 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple regimen (rabeprazole + amoxicillin + clarithromycin + bismuth potassium citrate) for 10 days followed by bismuth-placebo for 21 days (Group A1)
Number of subjects: 430
Study 26879784 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple regimen (rabeprazole + amoxicillin + clarithromycin + bismuth potassium citrate) for 10 days followed by bismuth potassium citrate for 21 days (Group A2)
Number of subjects: 430
Study 26879784 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple regimen for 10 days followed by rabeprazole for 14 days in duodenal ulcer patients
Number of subjects: 430
Study 26879784 — intervention group
Group type: COMPARATOR
Intervention: Symptoms improvement status (pain, burning sensation, reflux, belching, nausea, and vomiting)
Number of subjects: 430
Study 24658878 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception condition (initially told 6 MVCs, then asked to perform 12)
Number of subjects: 30
Study 24658878 — intervention group
Group type: COMPARATOR
Intervention: Control condition (informed of 12 MVCs)
Number of subjects: 30
Study 24658878 — intervention group
Group type: COMPARATOR
Intervention: Unknown condition (not informed of MVCs, stopped after 12)
Number of subjects: 30
Study 22311056 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (100-125 U)
Number of subjects: 25
Study 22311056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20579305 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedure CTA review
Number of subjects: 26
Study 20579305 — intervention group
Group type: COMPARATOR
Intervention: No preprocedure CTA review
Number of subjects: 26
Study 18820977 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polyethylene glycol (Group A)
Number of subjects: 129
Study 18820977 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (Group B)
Number of subjects: 129
Study 18820977 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined complications (SSI and anastomotic failure) (Group A)
Number of subjects: 129
Study 18820977 — intervention group
Group type: COMPARATOR
Intervention: Combined complications (SSI and anastomotic failure) (Group B)
Number of subjects: 129
Study 16076330 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 45
Study 16076330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11974895 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow inhalation of fluticasone dipropionate (DFP) (> 100 L/min)
Number of subjects: 13
Study 11974895 — intervention group
Group type: COMPARATOR
Intervention: Medium-flow inhalation of fluticasone dipropionate (DFP) (70 L/min)
Number of subjects: 13
Study 11974895 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone (BDP)
Number of subjects: 13
Study 10447899 — intervention group
Group type: EXPERIMENTAL
Intervention: atropine+meperidine
Number of subjects: 76
Study 10447899 — intervention group
Group type: EXPERIMENTAL
Intervention: glycopyrrolate+meperidine
Number of subjects: 76
Study 10447899 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 76
Study 10447899 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study 7772974 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (nebulized 4% lidocaine, 20 ml via oropharynx + transtracheal injection of 4% lidocaine, 3 ml)
Number of subjects: 40
Study 7772974 — intervention group
Group type: COMPARATOR
Intervention: Nerve block (bilateral glossopharyngeal and superior laryngeal nerve blocks with 2% lidocaine, 0.5‐2 ml per injection site + transtracheal injection of 4% lidocaine, 3 ml)
Number of subjects: 40
Study 7772974 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 2182430 — intervention group
Group type: EXPERIMENTAL
Intervention: L10 protocol
Number of subjects: 250
Study 2182430 — intervention group
Group type: EXPERIMENTAL
Intervention: L10M protocol
Number of subjects: 250
Study 2182430 — intervention group
Group type: COMPARATOR
Intervention: L2 protocol
Number of subjects: 250
Study 2182430 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 250
Study 2182430 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission (CR)
Number of subjects: 250
Study 2182430 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 250
Study 2182430 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse rates after continuous CR
Number of subjects: 250
Study 2182430 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrelapse survival
Number of subjects: 250
Study 2182430 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in second or later remission
Number of subjects: 250
Study 219267 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin fraction V, 60 mg/sq m, twice weekly during the initial six weeks of chemotherapy
Number of subjects: 0
Study 219267 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin fraction V, 20 mg/sq m, twice weekly during the initial six weeks of chemotherapy
Number of subjects: 0
Study 219267 — intervention group
Group type: COMPARATOR
Intervention: No thymosin treatment during the initial six weeks of chemotherapy
Number of subjects: 0
Study 31680138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carb test meal (MTT-HC) at 09:00 and high-fat meal (MTT-HF) at 15:40
Number of subjects: 29
Study 31680138 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal (MTT-HF) at 09:00 and high-carb test meal (MTT-HC) at 15:40
Number of subjects: 29
Study 30339627 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) at a dosage of 1000 mg/m every 2 weeks for 6 months
Number of subjects: 70
Study 30339627 — intervention group
Group type: COMPARATOR
Intervention: S-1 at a dosage of 80 mg/m/d for 28 days every 6 weeks for 6 months
Number of subjects: 70
Study 27223884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led Internet-based Learning and Self-care program
Number of subjects: 0
Study 26022410 — intervention group
Group type: EXPERIMENTAL
Intervention: CBASP (22 sessions)
Number of subjects: 60
Study 26022410 — intervention group
Group type: COMPARATOR
Intervention: ESC plus clinical management (ESC/CM)
Number of subjects: 60
Study 23202265 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cancer treatment subsidy
Number of subjects: 0
Study 23202265 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced price of screening by 10 cents
Number of subjects: 0
Study 23202265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21998346 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention
Number of subjects: 652
Study 21998346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 652
Study 18287375 — intervention group
Group type: EXPERIMENTAL
Intervention: Food plus micronutrient capsule (MN) containing 30 mg iron/d
Number of subjects: 61
Study 18287375 — intervention group
Group type: COMPARATOR
Intervention: Food supplement (control group)
Number of subjects: 61
Study 18287375 — intervention group
Group type: EXPERIMENTAL
Intervention: No inflammation group (baseline and 3 months)
Number of subjects: 61
Study 17668991 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal screening offered
Number of subjects: 97
Study 17668991 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal screening refused
Number of subjects: 97
Study 17668991 — intervention group
Group type: EXPERIMENTAL
Intervention: False negative result on screening
Number of subjects: 97
Study 12838091 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification-based physical therapy
Number of subjects: 78
Study 12838091 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based therapy
Number of subjects: 78
Study 12838091 — intervention group
Group type: COMPARATOR
Intervention: Classification-based therapy
Number of subjects: 78
Study 10846913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg every 6 hours intravenously
Number of subjects: 76
Study 10846913 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg every 6 hours intravenously
Number of subjects: 76
Study 9171907 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 38
Study 9171907 — intervention group
Group type: COMPARATOR
Intervention: Medication clinic approach
Number of subjects: 38
Study 1303845 — intervention group
Group type: EXPERIMENTAL
Intervention: Benadryl before the first transfusion
Number of subjects: 73
Study 1303845 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone before the second transfusion
Number of subjects: 73
Study 1303845 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone before the first transfusion
Number of subjects: 73
Study 1303845 — intervention group
Group type: COMPARATOR
Intervention: Benadryl before the second transfusion
Number of subjects: 73
Study 3971390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinca alkaloids (VA)
Number of subjects: 63
Study 3971390 — intervention group
Group type: COMPARATOR
Intervention: Control (no VA)
Number of subjects: 63
Study 29420360 — intervention group
Group type: EXPERIMENTAL
Intervention: REAL+RAT (20 min of real dual-tDCS associated with RAT)
Number of subjects: 21
Study 29420360 — intervention group
Group type: COMPARATOR
Intervention: SHAM+RAT (20 min of sham dual-tDCS associated with RAT)
Number of subjects: 21
Study 27129767 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezūm System thermal therapy (thermal water vapor at 103°C)
Number of subjects: 197
Study 27129767 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezūm System thermal therapy
Number of subjects: 197
Study 27129767 — intervention group
Group type: COMPARATOR
Intervention: Control (rigid cystoscopy with simulated active treatment sounds)
Number of subjects: 197
Study 24385026 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous passive drainage
Number of subjects: 246
Study 24385026 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 246
Study 22248352 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (200/6 µg, two inhalations bd)
Number of subjects: 50
Study 22248352 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (200 µg, two inhalations bd)
Number of subjects: 50
Study 22248352 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 50
Study 20457579 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive home visits by trained community nurses
Number of subjects: 651
Study 20457579 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 651
Study 18777420 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical attachment in Primary Health Care (1-week duration)
Number of subjects: 0
Study 16024853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide 2 mg
Number of subjects: 27
Study 16024853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide 5 mg
Number of subjects: 27
Study 16024853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide 13 mg
Number of subjects: 27
Study 16024853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (all dosages)
Number of subjects: 27
Study 12465720 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon treatment for 13 weeks followed by balloon for 52 weeks
Number of subjects: 42
Study 12465720 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment for 13 weeks followed by balloon for 52 weeks
Number of subjects: 42
Study 12465720 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon treatment for 52 weeks
Number of subjects: 42
Study 12465720 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (not specified how achieved)
Number of subjects: 42
Study 12465720 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 42
Study 10591384 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg of rt-PA (n = 272)
Number of subjects: 613
Study 10591384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 275)
Number of subjects: 613
Study 10591384 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg of rt-PA
Number of subjects: 613
Study 10591384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 9121997 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype E2O in hypertensives
Number of subjects: 134
Study 9121997 — intervention group
Group type: COMPARATOR
Intervention: Genotype E2O in normotensives
Number of subjects: 134
Study 9121997 — intervention group
Group type: COMPARATOR
Intervention: MspI and HindIII RFLP analysis
Number of subjects: 134
Study 9121997 — intervention group
Group type: COMPARATOR
Intervention: EcoT141 RFLP analysis
Number of subjects: 134
Study 1655262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 874
Study 1655262 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 874
Study 1655262 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 874
Study 1655262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril, Enalapril, Captopril
Number of subjects: 874
Study 6809108 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanga pant with Kanga pad
Number of subjects: 51
Study 6809108 — intervention group
Group type: COMPARATOR
Intervention: Sandra pant with Bambi pad
Number of subjects: 51
Study 6809108 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanga pant
Number of subjects: 51
Study 6809108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambi pad
Number of subjects: 51
Study 31994638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamojunto drug use prevention program
Number of subjects: 6176
Study 30578922 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 277
Study 28017403 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination with rVSV-ZEBOV (2×10^7 plaque-forming units administered intramuscularly)
Number of subjects: 5837
Study 28017403 — intervention group
Group type: COMPARATOR
Intervention: Delayed vaccination (21 days after randomisation)
Number of subjects: 5837
Study 28017403 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination in non-randomised clusters
Number of subjects: 5837
Study 28017403 — intervention group
Group type: COMPARATOR
Intervention: Delayed vaccination plus all eligible contacts and contacts of contacts never vaccinated in immediate clusters
Number of subjects: 5837
Study 28017403 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination
Number of subjects: 5837
Study 28039296 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Dance plus brief education for falls prevention
Number of subjects: 82
Study 28039296 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only brief education
Number of subjects: 82
Study 24149855 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) combined with dynamic fascial sutures (DFS)
Number of subjects: 87
Study 23085185 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining a vulnerable individual (e.g., elderly man)
Number of subjects: 66
Study 23085185 — intervention group
Group type: COMPARATOR
Intervention: Imagining an able-bodied individual (e.g., strong youthful male)
Number of subjects: 66
Study 20027347 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaferon (pediatric formulation)
Number of subjects: 0
Study 20027347 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17342417 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg for 8 weeks and atorvastatin 80 mg for the final 8 weeks (aggressive treatment)
Number of subjects: 100
Study 17342417 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg (conventional treatment)
Number of subjects: 100
Study 14693617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 70
Study 14693617 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium
Number of subjects: 70
Study 11586013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(12) cream containing avocado oil
Number of subjects: 13
Study 11586013 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 13
Study 9479684 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group (n = 20)
Number of subjects: 35
Study 9479684 — intervention group
Group type: COMPARATOR
Intervention: Non-PTSD group (n = 15)
Number of subjects: 35
Study 8113063 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat Smart School Nutrition Program (food service intervention)
Number of subjects: 0
Study 3364148 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with plain bupivacaine 0.5%
Number of subjects: 19
Study 3364148 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with bupivacaine 0.5% in glucose 8%
Number of subjects: 19
Study 30581236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric Oxide (NO) added to the gas phase of the extracorporeal circuit during cardiopulmonary bypass
Number of subjects: 198
Study 28539168 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS) in the form of two bottles a day of β‐hydroxy‐β‐methylbutyrate (HMB)
Number of subjects: 107
Study 28539168 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet plus ONS (IG)
Number of subjects: 107
Study 28539168 — intervention group
Group type: COMPARATOR
Intervention: Standard diet only (CG)
Number of subjects: 107
Study 28539168 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS
Number of subjects: 107
Study 25577032 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) infusion
Number of subjects: 40
Study 25577032 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 40
Study 23468196 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5‐mm ultrathin colonoscope (UTC)
Number of subjects: 203
Study 23468196 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscope
Number of subjects: 203
Study 21238659 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal mobilization (MIN)
Number of subjects: 177
Study 21238659 — intervention group
Group type: COMPARATOR
Intervention: Complete esophageal dissection (MAX)
Number of subjects: 177
Study 19108790 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg
Number of subjects: 100
Study 19108790 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 microg/kg
Number of subjects: 100
Study 19108790 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg/kg
Number of subjects: 100
Study 19108790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 100
Study 15982632 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to supervisors
Number of subjects: 36
Study 15982632 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to workgroups
Number of subjects: 36
Study 15982632 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to individuals
Number of subjects: 36
Study 15982632 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 12665145 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 71
Study 12665145 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 71
Study 12665145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical
Number of subjects: 71
Study 12665145 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 71
Study 14986633 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9553904 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-year tobacco prevention curriculum (five 45-minute lessons per year)
Number of subjects: 8
Study 9553904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tobacco prevention curriculum)
Number of subjects: 8
Study 7800186 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg)
Number of subjects: 40
Study 7800186 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.1 mg/kg)
Number of subjects: 40
Study 7800186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study 3287999 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation with intramuscular papaveretum
Number of subjects: 40
Study 3287999 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular papaveretum alone
Number of subjects: 40
Study 31523014 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker-based intervention with behavioral change communication through regular home visits.
Number of subjects: 1242
Study 31523014 — intervention group
Group type: COMPARATOR
Intervention: Usual care in the community (Control group).
Number of subjects: 1242
Study 29135664 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 1 (acetaminophen)
Number of subjects: 52
Study 29135664 — intervention group
Group type: COMPARATOR
Intervention: Step 2 (acetaminophen and tramadol)
Number of subjects: 52
Study 25932999 — intervention group
Group type: EXPERIMENTAL
Intervention: Old RBC transfusion (>15 days storage)
Number of subjects: 20
Study 25932999 — intervention group
Group type: COMPARATOR
Intervention: Fresh RBC transfusion (<10 days storage)
Number of subjects: 20
Study 25932999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Old and Fresh RBC transfusion)
Number of subjects: 20
Study 25932999 — intervention group
Group type: EXPERIMENTAL
Intervention: Old RBC transfusion
Number of subjects: 20
Study 22658588 — intervention group
Group type: EXPERIMENTAL
Intervention: C(1h) - 6 mg kg(‐1) caffeine consumed 1 hour prior to exercise
Number of subjects: 14
Study 22658588 — intervention group
Group type: EXPERIMENTAL
Intervention: C(peak) - 6 mg kg(‐1) caffeine consumed at peak serum concentration
Number of subjects: 14
Study 22658588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14